润都股份(002923.SZ)：公司1类创新药盐酸去甲乌药碱注射液目前仍在国家药监局的药品注册审评阶段

Core Viewpoint - Rundu Co., Ltd. is currently in the drug registration review phase for its innovative drug, Dexmedetomidine Hydrochloride Injection, with the National Medical Products Administration of China, and is progressing normally. The company may consider expanding into overseas markets based on domestic market development and sales performance [1] Group 1 - The innovative drug Dexmedetomidine Hydrochloride Injection is under review by the National Medical Products Administration of China [1] - The company is actively progressing through the drug registration process [1] - Future expansion into overseas markets is a possibility depending on domestic market conditions [1]